Top
Summary
All studies
Mortality
Serious outcomes
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
 
Analgesics
Antiandrogens
Antihistamines
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
c19early.org COVID-19 treatment researchrNAPc2rNAPc2 (more..)
Metformin Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta Thermotherapy Meta
Melatonin Meta

Outcomes in COVID-19 rNAPc2 studies

0 0.5 1 1.5+ All studies -65% 1 156 Improvement, Studies, Patients Relative Risk Mortality -65% 1 156 RCTs -65% 1 156 Late -65% 1 156 RNAPc2 for COVID-19 c19early.org February 2025 FavorsrNAPc2 Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ASPEN-COVID-19 Hess (RCT) -65% 1.65 [0.68-4.04] death 11/76 7/80 OT​1 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.27 Late treatment -65% 1.65 [0.68-4.04] 11/76 7/80 65% higher risk All studies -65% 1.65 [0.68-4.04] 11/76 7/80 65% higher risk 1 rNAPc2 COVID-19 study c19early.org February 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.27 Effect extraction pre-specified(most serious outcome) 1 OT: comparison with other treatment Favors rNAPc2 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ASPEN-COVID-19 Hess (RCT) -65% 1.65 [0.68-4.04] 11/76 7/80 OT​1 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.27 Late treatment -65% 1.65 [0.68-4.04] 11/76 7/80 65% higher risk All studies -65% 1.65 [0.68-4.04] 11/76 7/80 65% higher risk 1 rNAPc2 COVID-19 mortality result c19early.org February 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.27 1 OT: comparison with other treatment Favors rNAPc2 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ASPEN-COVID-19 Hess (RCT) -65% 1.65 [0.68-4.04] death 11/76 7/80 OT​1 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.27 Late treatment -65% 1.65 [0.68-4.04] 11/76 7/80 65% higher risk All studies -65% 1.65 [0.68-4.04] 11/76 7/80 65% higher risk 1 rNAPc2 COVID-19 serious outcome c19early.org February 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.27 Effect extraction pre-specified(most serious outcome) 1 OT: comparison with other treatment Favors rNAPc2 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ASPEN-COVID-19 Hess (RCT) -65% 1.65 [0.68-4.04] death 11/76 7/80 OT​1 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.27 Late treatment -65% 1.65 [0.68-4.04] 11/76 7/80 65% higher risk All studies -65% 1.65 [0.68-4.04] 11/76 7/80 65% higher risk 1 rNAPc2 COVID-19 Randomized Controlled Trial c19early.org February 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.27 Effect extraction pre-specified(most serious outcome) 1 OT: comparison with other treatment Favors rNAPc2 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ASPEN-COVID-19 Hess (RCT) -65% 1.65 [0.68-4.04] 11/76 7/80 OT​1 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.27 Late treatment -65% 1.65 [0.68-4.04] 11/76 7/80 65% higher risk All studies -65% 1.65 [0.68-4.04] 11/76 7/80 65% higher risk 1 rNAPc2 COVID-19 RCT mortality result c19early.org February 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.27 1 OT: comparison with other treatment Favors rNAPc2 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ASPEN-COVID-19 Hess (RCT) -65% 1.65 [0.68-4.04] death 11/76 7/80 OT​1 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.27 Late treatment -65% 1.65 [0.68-4.04] 11/76 7/80 65% higher risk All studies -65% 1.65 [0.68-4.04] 11/76 7/80 65% higher risk 1 rNAPc2 COVID-19 peer reviewed studies c19early.org February 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.27 Effect extraction pre-specified(most serious outcome) 1 OT: comparison with other treatment Favors rNAPc2 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ASPEN-COVID-19 Hess (RCT) -65% 1.65 [0.68-4.04] death 11/76 7/80 OT​1 Improvement, RR [CI] Treatment Control RNAPc2 COVID-19 outcomes c19early.org February 2025 1 OT: comparison with other treatment Favors rNAPc2 Favors control
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit